CERKL Antibody

What is CERKL protein and what are its known functions?

CERKL (Ceramide Kinase-Like) protein is structurally similar to ceramide kinases but does not demonstrate ceramide kinase activity, making it an orphan lipid kinase. Research suggests CERKL primarily functions to support photoreceptor cells in the retina, which are critical for light detection in vertebrate vision systems . The protein appears to provide protection against cellular damage in oxidative environments, with overexpression of CERKL shown to protect cells from apoptosis under oxidative stress conditions . Despite its structural similarities to ceramide kinases, there is currently no experimental evidence supporting CERKL kinase activity on ceramides, leaving its precise biochemical function somewhat unclear .

What applications are CERKL antibodies commonly used for?

CERKL antibodies are suitable for multiple experimental applications in research settings. Based on available commercial antibodies, the primary applications include:

• Western blot (WB) analysis for protein detection and quantification

• Immunohistochemistry on paraffin-embedded sections (IHC-P) for tissue localization

• Immunocytochemistry/immunofluorescence (ICC/IF) for cellular and subcellular localization

In published research, CERKL antibodies have been successfully used to detect the protein in various sample types including mouse lung tissue lysates, human prostate cancer tissue, human pancreatic tissue, and human breast adenocarcinoma cell lines (MCF7) . Most commercially available CERKL antibodies are tested and validated for reactivity with mouse and human samples, though cross-reactivity with other species may occur due to sequence homology.

What are the critical considerations for CERKL antibody validation?

Antibody validation is essential for ensuring experimental reproducibility and reliability. For CERKL antibodies specifically, validation should include:

• Verification of specificity using appropriate positive and negative controls

• Confirmation of the expected band size (~63 kDa for full-length CERKL) in Western blots

• Cross-validation using multiple detection techniques (WB, IHC, ICC)

• Ideally, using knockout (KO) or knockdown (KD) controls to confirm antibody specificity

With the increased availability of CRISPR technologies, knockout cell lines and model organisms provide excellent negative controls for antibody specificity testing . Researchers should remember that the responsibility for proving specificity lies with the purchaser rather than the vendor, making independent validation crucial before using any CERKL antibody for critical experiments .

What are the typical expression patterns of CERKL in human tissues?

CERKL expression has been detected across multiple human tissues, with particularly notable expression in the retina. RT-PCR analysis has been used to examine CERKL splicing patterns across human tissue panels. The expression profile varies depending on the specific splicing variant being detected, with four main variants (CERKLa, CERKLb, CERKLc, and CERKLd) identified through research .

In immunohistochemical analyses, CERKL protein has been detected in human prostate cancer tissue and pancreatic tissue, suggesting expression beyond retinal tissues . Understanding tissue-specific expression patterns is critical for researchers designing experiments to study CERKL function in different physiological and pathological contexts.

How can researchers distinguish between different CERKL isoforms?

CERKL has multiple splicing variants that have been identified in human tissues, particularly the retina. Four main isoforms (CERKLa, CERKLb, CERKLc, and CERKLd) have been characterized . Distinguishing between these variants requires careful experimental design:

• RT-PCR with isoform-specific primers: Researchers can design primers that specifically amplify each variant based on their unique exon compositions. The following primer sets have been used for this purpose:

  • For CERKLa and CERKLb: RT_CERKLab_F and RT_CERKLab_R

  • For CERKLc: RT_CERKLc_F and RT_CERKLcd_R

  • For CERKLd: RT_CERKLd_F and RT_CERKLcd_R

• Western blot analysis: Different isoforms may have distinct molecular weights that can be detected by Western blot. Researchers should be aware of these size differences when interpreting Western blot results.

• Recombinant expression: For functional studies, researchers can clone and express individual CERKL isoforms with epitope tags (such as HA or GST tags) to study their specific properties .

What experimental controls are essential when using CERKL antibodies?

When using CERKL antibodies, comprehensive controls are essential for result interpretation and validation:

• Negative controls:

  • Knockout or knockdown samples (CRISPR-modified cell lines or siRNA-treated samples)

  • Secondary antibody-only controls to assess non-specific binding

  • Pre-immune serum controls (for polyclonal antibodies)

• Positive controls:

  • Tissues or cells known to express CERKL (e.g., retinal samples)

  • Recombinant CERKL protein expression

  • Overexpression systems using CERKL expression vectors

• Specificity controls:

  • Antibody pre-absorption with immunizing peptide

  • Testing for cross-reactivity with related proteins

  • Parallel testing with multiple antibodies targeting different epitopes of CERKL

Including these controls helps distinguish genuine signals from artifacts and ensures experimental reproducibility. Particularly important is the use of CRISPR-generated knockout samples as negative controls, which has become much more accessible and provides definitive evidence of antibody specificity .

How can CERKL subcellular localization be accurately determined?

Determining the subcellular localization of CERKL requires multiple complementary approaches:

• Immunofluorescence microscopy:

  • Co-localization with organelle-specific markers is essential

  • For CERKL, markers for ER (calnexin), Golgi (GM130), and endosomes (EEA1) have been used

  • Counter-staining with nuclear dyes like DAPI helps provide cellular context

  • Confocal microscopy provides better resolution of subcellular compartments

• Subcellular fractionation:

  • Sucrose gradient fractionation can separate cellular compartments

  • Western blot analysis of fractions can identify which compartments contain CERKL

  • Research has shown CERKL distributes to fractions containing Trans-Golgi (TGN38), Golgi (GM130), and ER (PDI) markers, with higher abundance in Trans-Golgi and Golgi fractions

• Biochemical approaches:

  • Proteinase protection assays to determine membrane topology

  • Co-immunoprecipitation to identify interacting partners in specific compartments

• In silico predictions:

  • Computational tools like PSORT, ProSLP v2.0, ESLPred, and SubLoc v1.0 can provide preliminary localization predictions

What considerations are important when studying CERKL in retinal research?

CERKL is particularly relevant in retinal research due to its association with retinitis pigmentosa. Key considerations include:

• Tissue preparation:

  • Retinal tissue requires careful fixation and processing to preserve structure

  • Fresh tissue is preferred for protein and RNA extraction

  • Special considerations for embedding and sectioning are necessary for immunohistochemistry

• Disease models:

  • CERKL mutations, particularly the R257X mutation associated with retinitis pigmentosa, can be studied using site-directed mutagenesis

  • Comparing wild-type CERKL with disease-associated mutants provides insights into pathological mechanisms

• Functional assays:

  • Oxidative stress protection assays are relevant given CERKL's protective function

  • Apoptosis assays can measure the anti-apoptotic effects of CERKL

  • Lipid-protein overlay assays can assess CERKL's interaction with sphingolipids and phosphoinositides

• Expression systems:

  • Heterologous expression in cell lines may not fully recapitulate retinal cell behavior

  • Primary retinal cell cultures or organoids may provide more physiologically relevant models

How should contradictory results with different CERKL antibodies be interpreted?

Researchers often encounter contradictory results when using different antibodies against the same target. For CERKL specifically:

• Epitope considerations:

  • Different antibodies target different epitopes, which may be differentially accessible in various experimental conditions

  • Some epitopes may be masked by protein-protein interactions or post-translational modifications

  • Some antibodies may recognize specific isoforms but not others

• Validation approach:

  • Cross-validate findings using multiple antibodies targeting different regions of CERKL

  • Use genetic approaches (knockdown/knockout) to confirm specificity

  • Compare polyclonal versus monoclonal antibodies, which offer different advantages

• Experimental conditions:

  • Fixation methods significantly impact epitope preservation and accessibility

  • Buffer compositions and blocking agents may affect antibody performance

  • Incubation times and temperatures should be optimized for each antibody

• Data integration:

  • When results conflict, prioritize findings confirmed by multiple approaches

  • Consider whether discrepancies might reflect biological reality (e.g., context-dependent protein conformations)

  • Report all contradictory findings transparently in publications

What is the optimal protocol for Western blot analysis of CERKL?

For optimal Western blot detection of CERKL, researchers should consider the following protocol elements:

• Sample preparation:

  • Use appropriate lysis buffers (e.g., 20 mM MOPS pH 7.2, 2 mM EGTA, 1 mM dithiothreitol, 10% glycerol, with protease inhibitors)

  • Sonication helps ensure complete lysis and protein extraction

  • Fresh samples yield better results than frozen ones

• Gel electrophoresis:

  • 10% polyacrylamide SDS-PAGE gels are suitable for resolving CERKL (predicted size: 63 kDa)

  • Include positive controls (e.g., recombinant CERKL) and molecular weight markers

• Transfer and detection:

  • Transfer to 0.45 μm PVDF membranes

  • Commercially validated CERKL antibodies like ab222828 can be used at 1/1000 dilution

  • Secondary antibodies (such as Goat Anti-Rabbit IgG) typically work well at 1/10000 dilution

• Analysis considerations:

  • Be aware that different CERKL isoforms may show different banding patterns

  • The main CERKL band should appear at approximately 63 kDa

  • Multiple bands may represent different isoforms or post-translational modifications

What approaches can be used to study CERKL protein-lipid interactions?

CERKL's interaction with lipids can be studied through several methodologies:

• Lipid-protein overlay assays:

  • SphingoStrips™ and PIP Strips™ contain nitrocellulose-immobilized sphingolipids and phosphoinositides

  • GST-tagged recombinant CERKL isoforms can be incubated with these strips

  • Binding is detected using anti-GST antibodies followed by HRP-conjugated secondary antibodies

• Recombinant protein production:

  • CERKL isoforms can be expressed as GST fusion proteins

  • Expression in BL21 Codon Plus E. coli cells helps avoid premature truncation due to biased codon usage

  • Purification using glutathione-sepharose beads yields purified protein for binding assays

• Experimental conditions:

  • Membranes are typically blocked with 3% BSA in TBST

  • Protein concentration of 0.5 μg/ml is recommended for binding assays

  • Overnight incubation at 4°C provides optimal binding conditions

This approach has been successfully used to characterize CERKL's binding preferences among various lipid species, providing insights into its potential biological functions despite its status as an orphan lipid kinase.

How can researchers effectively study CERKL mutations associated with retinal diseases?

Studying disease-associated CERKL mutations requires systematic approaches:

• Mutation generation:

  • Site-directed mutagenesis can introduce specific mutations (like the RP-associated R257X mutation)

  • Primers can be designed to introduce the desired nucleotide change (e.g., 847C>T for R257X)

  • Both N-terminal and C-terminal epitope tags can be used depending on the mutation location

• Expression systems:

  • Mammalian expression systems (HEK293T, COS-7) are suitable for studying CERKL variants

  • Transfection can be performed using lipid-based reagents like Lipofectamine™ 2000

  • Expression should be verified by Western blot or immunofluorescence

• Functional comparisons:

  • Compare wild-type and mutant CERKL in various assays:

    • Subcellular localization

    • Lipid binding properties

    • Protective effect against oxidative stress

    • Protein-protein interactions

• Disease modeling:

  • Patient-derived cells or iPSCs can provide physiologically relevant models

  • CRISPR-engineered cell lines with specific mutations allow controlled comparisons

  • Animal models with equivalent mutations may recapitulate disease phenotypes

What alternative approaches beyond antibodies can be used to study CERKL?

While antibodies remain essential tools, complementary approaches provide additional insights:

• Fluorescent protein fusions:

  • GFP, YFP, or mCherry-tagged CERKL constructs allow live-cell imaging

  • These constructs can reveal dynamic localization and trafficking patterns

  • Split-fluorescent protein systems can study protein-protein interactions

• Proximity labeling:

  • BioID or APEX2 fusions to CERKL can identify proximal proteins in living cells

  • These approaches map the CERKL interactome without relying on stable interactions

  • May reveal transient interactions missed by co-immunoprecipitation

• Mass spectrometry approaches:

  • Quantitative proteomics comparing wild-type and CERKL-deficient samples

  • PTM analysis to identify regulatory modifications on CERKL

  • CERKL interactome studies using affinity purification-mass spectrometry

• Genomic approaches:

  • RNA-seq to identify genes regulated downstream of CERKL

  • ChIP-seq if CERKL has any nuclear functions

  • CRISPR screening to identify synthetic interactions

These complementary approaches can overcome limitations of antibody-based methods and provide systems-level insights into CERKL function.

How should researchers interpret CERKL's role in oxidative stress protection?

CERKL has been implicated in protecting cells from oxidative stress, which is particularly relevant for retinal research:

• Experimental approaches:

  • Compare survival of CERKL-expressing versus control cells under oxidative conditions

  • Measure ROS levels using fluorescent indicators in the presence/absence of CERKL

  • Assess mitochondrial function and integrity in CERKL-manipulated cells

• Mechanism investigation:

  • Determine whether CERKL directly scavenges ROS or acts indirectly

  • Investigate whether CERKL regulates antioxidant enzymes or pathways

  • Explore connections between CERKL's lipid binding and antioxidant functions

• Tissue relevance:

  • The retina experiences high oxidative stress due to light exposure and high metabolism

  • CERKL's protective function may explain why its mutation causes retinal degeneration

  • Comparative studies across tissues with different oxidative loads may be informative

Understanding this function could reveal therapeutic strategies for retinitis pigmentosa and other oxidative stress-related conditions.